Drugs / 91-day Levonorgestrel Oral Contraceptive
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | SEASONIQUE | — | 2006-05-25 | fda.gov ↗ |
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00781456 | Jan 2009 → Aug 2011 | migraine disorder | Duramed Research | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00117273 | Jun 2005 → Jun 2006 | — | Duramed Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 91-day Levonorgestrel Oral Contraceptive | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00781456 ↗ |
| Known as | Seasonique | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00117273 ↗ |
| Route | Oral | “91-day extended cycle oral contraceptive” NCT00781456 ↗ |